{"filings":[{"id":452276,"accession_number":"0001104659-26-061773","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-05-15T11:07:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel reports Q1 net loss $12.7M; FDA sets Nov 14 PDUFA for at-home IGALMI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted sNDA for IGALMI at-home use in agitation associated with bipolar/schizophrenia; PDUFA date Nov 14, 2026.","Net revenue $206K (up 23% YoY from $168K); net loss $12.7M vs $7.3M in Q1 2025.","Engaged MTS Health Partners to explore strategic options including sale, merger, or collaboration.","Cash and equivalents $17.2M as of Mar 31, 2026; company in compliance with credit covenants.","R&D down to $3.0M from $4.6M due to SERENITY trial completion; SG&A up to $7.2M from $5.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":206000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94983,"accession_number":"0001104659-26-044952","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"BioXcel Therapeutics issues warrants to purchase 1.35M shares at $0.01 per share under credit amendment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On April 15, 2026, BioXcel Therapeutics granted lenders warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share.","The warrants were issued pursuant to the Ninth Amendment to the Credit Agreement and Guaranty, dated April 19, 2022.","The Company also entered into a Fourth Amended and Restated Registration Rights Agreement with the lenders to register shares underlying the warrants.","The lenders include entities such as Oaktree-TCDRS Strategic Credit, LLC, Oaktree Specialty Lending Corporation, and others.","The warrants expire on the seventh anniversary of issuance and were issued in reliance on Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94982,"accession_number":"0001104659-26-038174","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel announces FDA acceptance of sNDA for IGALMI in at-home agitation; PDUFA Nov 14, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted supplemental New Drug Application for IGALMI (dexmedetomidine) for acute agitation in bipolar disorders or schizophrenia in outpatient setting.","PDUFA target action date is November 14, 2026.","If approved, IGALMI would be the first sublingual film for at-home agitation treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107744,"accession_number":"0001104659-26-035661","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel posts Q4 net loss $12.5M, IGALMI revenue falls; sNDA filed for at-home use","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 IGALMI revenue $256K vs $366K in Q4 2024; full year $642K vs $2.3M.","Net loss Q4 $12.5M ($10.9M Q4 2024); full year $69.9M ($59.6M 2024).","Cash $28.8M at Dec 31, 2025; operating cash use $57.6M in 2025 vs $72M in 2024.","sNDA submitted Jan 2026 for IGALMI in at-home agitation; potential approval year-end 2026.","Appointed Mark Pavao as Interim CCO to lead launch plans for IGALMI at-home."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107743,"accession_number":"0001104659-26-026409","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioXcel Therapeutics raises $7.8M in registered direct offering and amends prior warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,480,294 common shares and pre-funded warrants for 2,020,491 shares at combined $1.739/unit, plus accompanying warrants.","Gross proceeds ~$7.8M; placement agent fees 6% cash plus 180,031 warrants at $2.0175.","Warrant amendment reduces exercise price to $1.614 on 1,385,083 prior warrants and extends term to 5 years; investor paid ~$173k.","Proceeds used for working capital and general corporate purposes.","Offering closed March 11, 2026; common stock trades on Nasdaq under BTAI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107742,"accession_number":"0001104659-26-013840","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel updates IGALMI at-home opportunity: up to 86M annual episodes, sNDA pending","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated market assessment for IGALMI at-home use identifies up to 86M addressable annual episodes, up from prior 57-77M estimate.","sNDA seeking FDA approval for at-home use submitted last month; assessment based on SERENITY At-Home study and market research.","Prescribers project using IGALMI in ~70% of schizophrenia/bipolar disorder patients; patients expect use in ~80% of agitation episodes.","Claims data: ~2.3M treated patients experience frequent acute agitation at home; up to 1.8M may be eligible for IGALMI.","Payers indicated expectations for broad formulary coverage with standard adjudication controls; prescribers report moderate-high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107741,"accession_number":"0001104659-26-011595","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioXcel enters retention bonus agreements with key employees, CEO gets $650K after sNDA submission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO receives $650K bonus ($325K initial, $325K final); other key employees get $225K ($150K initial, $75K final).","Final payment due April 15, 2026, contingent on continued employment and no default under Oaktree credit agreement.","Final payment accelerates if company raises $25M+ capital or a change of control occurs before April 15, 2026.","Employees must repay bonuses if terminated for cause or resign without good reason before Dec 31, 2026 (or Sep 30, 2026 if only initial paid).","Agreements follow submission of sNDA for IGALMI for acute agitation in bipolar disorder or schizophrenia in outpatient setting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107740,"accession_number":"0001104659-26-004787","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel submits sNDA for at-home use of IGALMI for agitation in bipolar/schizophrenia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted sNDA to FDA on January 14, 2026 for IGALMI in the at-home setting.","IGALMI currently approved only under healthcare provider supervision since April 2022.","No FDA-approved at-home options exist for acute agitation in bipolar disorders or schizophrenia.","Seeking to expand IGALMI's label to cover broader at-home patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107739,"accession_number":"0001104659-26-002697","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel names Mark Pavao Interim CCO; plans sNDA for IGALMI at-home use","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Pavao appointed Interim Chief Commercial Officer to support potential IGALMI at-home launch.","Company plans to submit supplemental NDA this month for FDA approval of IGALMI for at-home use.","IGALMI targets acute agitation in bipolar disorders or schizophrenia; at-home expansion is key strategic move."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124116,"accession_number":"0001104659-25-121180","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioXcel stockholders approve reverse stock split authorization and elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five proposals passed at Dec 12 annual meeting; 44.68% of shares voted.","Directors June Bray, Sandeep Laumas, David Mack elected as Class I directors.","Ernst & Young ratified as independent auditor for FY2025.","Advisory say-on-pay approved with ~78% of votes cast (excl. broker non-votes).","Stockholders authorized reverse stock split of 1:2 to 1:20 to regain Nasdaq bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124115,"accession_number":"0001104659-25-109732","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel Q3 net loss $30.9M; plans sNDA for IGALMI at-home use in Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $98K from IGALMI, down from $214K YoY; cost of goods sold fell to $11K.","Net loss widened to $30.9M ($14.2M operating loss) from $13.7M loss a year ago; operating cash use $18.8M.","R&D expense rose to $8.7M (up $3.6M) due to SERENITY At-Home trial; SG&A fell to $5.4M.","Cash and equivalents $37.3M at Sep 30; raised $4.9M post-quarter via ATM.","Plans sNDA submission in early Q1 2026 for IGALMI at-home agitation treatment; revised addressable market to 57-77M annual episodes."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":386000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124114,"accession_number":"0001104659-25-108840","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioXcel reports positive Phase 3 safety and efficacy results for BXCL501 agitation in home setting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BXCL501 (sublingual dexmedetomidine) safe and well-tolerated in 12-week home-use study (SERENITY At-Home).","No increase in adverse events with repeat dosing; 81% of treated patients completed the study.","Exploratory efficacy: greater reduction in mCGI-S vs placebo (P<0.05); complete resolution higher with BXCL501 (P<.0001).","No patient on active arm discontinued due to TEAE; results support potential label expansion for unsupervised use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124113,"accession_number":"0001104659-25-104009","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel expects to submit IGALMI at-home sNDA early Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed SERENITY At-Home Phase 3 safety trial in August 2025; positive topline data.","Correlation study completed October 2025 with positive results supporting efficacy outcomes.","sNDA submission for at-home label expansion now expected early Q1 2026 (previously no firm date).","IGALMI currently approved only for acute agitation in bipolar/schizophrenia in supervised settings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124112,"accession_number":"0001104659-25-098992","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel Therapeutics reports strong correlation between clinician & caregiver agitation scales; sNDA planned Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Correlation study (N=33) shows ρ=0.89 (patient) and ρ=0.88 (informant) between PEC and mCGI-S scales, p<0.0001.","No serious adverse events; safety profile consistent with IGALMI label.","Results to be included in sNDA submission for BXCL501 planned for Q1 2026.","mCGI-S scale developed with FDA for at-home efficacy assessment of acute agitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140780,"accession_number":"0001104659-25-089773","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"BioXcel completes enrollment for mCGI-S/PEC study; sNDA submission expected Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Open-label study of ~30 patients evaluating mCGI-S vs PEC scale enrolled on Sept 13, 2025; results due Q4 2025.","sNDA for BXCL501 SERENITY At-Home program planned for Q1 2026, incorporating this and prior Phase 3 safety data.","Raised $37.3M from July 1 to Sept 15, 2025 via ATM ($27.6M) and warrant exercises ($9.7M).","As of Sept 12, 2025, shares outstanding totaled 19,646,801; cash expected to fund operations into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140779,"accession_number":"0001104659-25-088800","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel reports positive Phase 3 SERENITY At-Home data for BXCL501; agitation resolution significantly higher vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SERENITY At-Home trial: 246 patients randomized; BXCL501 showed significant mean reduction in mCGI-S score vs placebo at 2 hours (p<.05).","Complete resolution of agitation in 50% of BXCL501 arm vs 33% placebo overall (p<.0001); severe episodes resolved 61% vs 18% (p<.0001).","Efficacy maintained across repeated dosing and over 12-week duration; mean reduction of 1.2-1.4 in mCGI-S score.","Company revises addressable market estimate to 57-77M agitation episodes annually (from prior 23M) based on trial and survey data.","BXCL501 (IGALMI) is already FDA-approved for medically supervised settings; data supports potential label expansion for at-home use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140778,"accession_number":"0001104659-25-083402","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel Therapeutics' BXCL501 meets primary endpoint in SERENITY At-Home Phase 3 trial for agitation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 SERENITY At-Home trial met primary safety endpoint; no drug-related SAEs, syncope, or falls in 2,437 episodes treated with 120 mcg BXCL501.","No discontinuations due to tolerability in BXCL501 arm; adverse event profile consistent with approved IGALMI label.","Company plans sNDA submission for label expansion to at-home setting in Q1 2026; market opportunity estimated at 57–77 million annual episodes in US.","Exploratory efficacy data show greater percentage of patients achieved full agitation resolution with BXCL501 vs placebo, with consistent benefit across repeat dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140777,"accession_number":"0001104659-25-079880","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioXcel Therapeutics files prospectus supplement for up to $80M ATM stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to $80M of common stock via ATM program with Canaccord Genuity.","ATM program established April 3, 2025; supplement filed August 18, 2025.","Honigman LLP issued validity opinion on shares; counsel's opinion filed as Exhibit 5.1.","Shares to be sold through any method deemed an 'at the market' offering under Rule 415(a)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140776,"accession_number":"0001104659-25-079459","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel receives positive FDA pre-sNDA comments for BXCL501 at-home use; sNDA on track for Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided positive written feedback on August 14, 2025 for BXCL501 sNDA in agitation associated with bipolar disorders or schizophrenia for outpatient setting.","Pre-sNDA meeting originally scheduled for August 20, 2025 is cancelled as objectives accomplished based on FDA written responses.","Company believes sNDA regulatory package will be sufficient; submission remains on track for first quarter of 2026.","This expands potential use of BXCL501 (IGALMI) from inpatient to at-home treatment for acute agitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140775,"accession_number":"0001104659-25-079042","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel receives positive FDA preliminary comments ahead of pre-sNDA meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Positive preliminary FDA meeting comments received August 14, 2025.","Pre-sNDA meeting scheduled for August 20, 2025 to align on sNDA submission format and content.","Company evaluating feedback and plans to provide update next week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140774,"accession_number":"0001104659-25-076501","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel Q2 net loss $19.2M, cash $18.6M; SERENITY Phase 3 topline due August","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 IGALMI revenue $120K (down ~89% YoY from $1.1M); net loss $19.2M vs $8.3M in Q2 2024.","Operating loss improved to $15.9M from $17.3M YoY; R&D spending up to $10.3M from $8.0M.","Cash and equivalents $18.6M at June 30; post-quarter raised $11.5M from ATM and $3.6M from warrant exercises.","SERENITY At-Home Phase 3 trial for bipolar/schizophrenia complete; topline results expected August 2025.","FDA meeting in August to support potential sNDA for label expansion of IGALMI to at-home setting."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":288000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140773,"accession_number":"0001104659-25-076214","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioXcel Therapeutics raises $30.4M net, satisfies Oaktree financing covenant","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Raised $30.4M net from Nov 2024 ($6.2M), Mar 2025 ($13.0M), and ATM ($11.2M) financings, satisfying the Oaktree Financing Covenant.","Covenant required $29M net by Aug 15, 2025 or 30 days after SERENITY Phase 3 final readout; now satisfied.","As of Aug 8, 2025, BioXcel had 13,709,124 shares outstanding post-exercise of all pre-funded warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140772,"accession_number":"0001104659-25-075915","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioXcel presents at-home BXCL501 market opp: patients would use in 80% of episodes","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Market research shows ~3 episodes/month (36/year) per patient, vs prior 23M annual episodes estimate from claims data.","HCPs would prescribe BXCL501 for ~16% of their bipolar/schizophrenia patients based on target product profile.","Patients report they would use BXCL501 in 80% of at-home agitation episodes; pricing could reach $1,400+ per prescription.","At-home setting has no approved treatments; BXCL501 targets early intervention to prevent escalation.","SERENITY At-Home Phase 3 trial data (2,200+ episodes collected) results are upcoming."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140771,"accession_number":"0001104659-25-074514","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel announces publication of non-clinical study on dexmedetomidine in Frontiers in Pharmacology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study shows dexmedetomidine potently and reversibly regulates stress-mediated behaviors.","Dexmedetomidine exhibited higher in vitro potency than clonidine, lofexidine, or guanfacine.","Mitigated responses to acute and repeated stress after both acute and repeated dosing, with no loss of effect.","No withdrawal effects; no impact on motor function or cognition vs. diazepam or scopolamine.","Results support BXCL-501's potential for stress-related disorders beyond acute agitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140770,"accession_number":"0001104659-25-072900","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel completes enrollment (last patient last visit) in SERENITY At-Home Phase 3 trial for BXCL501","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SERENITY At-Home Phase 3 safety trial for BXCL501 120 mcg to treat acute agitation in bipolar/schizophrenia.","Enrolled >200 patients across 22 sites; no single site >11% of total patients.","Patient distribution balanced between bipolar disorders and schizophrenia.","Collected data from >2,200 agitation episodes; topline results expected in August 2025.","Topline results expected to be announced this month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140769,"accession_number":"0001104659-25-069149","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel submits pre-sNDA package to FDA for IGALMI outpatient label expansion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Pre-sNDA meeting package submitted July 21, 2025 for IGALMI (BXCL501) outpatient use.","FDA meeting scheduled for August 20, 2025 to align on sNDA content and format.","Expansion targets acute agitation in schizophrenia or bipolar disorders at-home setting.","Plans to reconfirm prior Type C meeting (March 6, 2024) support for 120 mcg dose development.","sNDA submission preparation ongoing; no guarantee of FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140768,"accession_number":"0001104659-25-067951","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel Therapeutics receives USPTO allowance for key IGALMI patent expiring 2043","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO allowed U.S. Patent Application No. 18/600,419 for single-dose oromucosal dexmedetomidine up to 120 mcg.","Claims cover acute agitation treatment in schizophrenia or bipolar disorder with QT prolongation <6 microseconds.","Allowed claims mirror the recommended IGALMI dosing regime for that patient subpopulation.","This will be the 14th Orange Book-listed patent for IGALMI, expiring January 12, 2043 subject to adjustment.","CFO Richard Steinhart signed the 8-K filed July 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158514,"accession_number":"0001104659-25-052704","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel Therapeutics granted Nasdaq listing extension to Sept 16, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel extended compliance deadline for MVLS Rule (minimum $35M market value for 10 consecutive days) to September 16, 2025.","Extension is subject to BioXcel meeting certain interim conditions set by the Panel.","Company previously faced potential delisting for failing to satisfy Nasdaq Listing Rule 5550(b)(2).","Decision follows review of BioXcel's compliance plan and strategies for long-term compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158513,"accession_number":"0001104659-25-047013","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel Q1 net loss $7.3M; SERENITY At-Home trial fully enrolled, data H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue from IGALMI fell to $168K in Q1 2025 from $582K in Q1 2024.","Net loss of $7.3M improved from $26.8M YoY on lower R&D and SG&A costs.","Cash and equivalents $31M as of March 31, 2025.","SERENITY At-Home pivotal Phase 3 trial fully enrolled; topline data expected H2 2025.","TRANQUILITY In-Care Phase 3 trial for Alzheimer's agitation is advancing toward initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":168000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158512,"accession_number":"0001104659-25-031713","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioXcel Therapeutics enters ATM equity distribution agreement for up to $8.135M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Equity Distribution Agreement with Canaccord Genuity LLC on April 3, 2025.","May sell up to $8,135,000 of common stock via at-the-market offerings under existing shelf registration.","Canaccord receives up to 3.0% commission on gross proceeds; Company reimburses certain expenses.","Shares sold through Nasdaq or other trading market at prevailing prices with no minimum price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176908,"accession_number":"0001104659-25-028776","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel Therapeutics Q4 net loss $10.9M; SERENITY Phase 3 trial 63% enrolled; cash ~$35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.9M in Q4 2024 vs $22.3M Q4 2023; full-year net loss $59.6M vs $179.1M.","IGALMI net revenue $366K in Q4 ($376K Q4 2023); full-year $2.3M vs $1.4M in 2023.","SERENITY At-Home Phase 3 trial enrollment at 63% (127/200 patients); topline data expected H2 2025.","Closed $14M equity financing, strengthening cash to ~$35M as of March 4, 2025 (from $29.9M Dec 31, 2024).","Cash used in operating activities $72M in 2024, down from $155M in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176907,"accession_number":"0001104659-25-026708","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioXcel Therapeutics receives Nasdaq delisting notice; intends to appeal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq delisting notice on March 20, 2025 for failing to meet $35M minimum MVLS requirement.","Company was granted 180-day period through March 19, 2025 to regain compliance but remained non-compliant.","Intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff's determination.","Appeal will stay delisting action pending outcome; common stock remains listed on Nasdaq in interim.","No assurance that Company will ultimately regain compliance and remain listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176906,"accession_number":"0001104659-25-026388","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel Therapeutics reaches 50% enrollment in SERENITY At-Home Phase 3 trial for BXCL501","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100 patients enrolled out of 200 expected (50% of total); 24 sites open as of March 20, 2025.","Trial evaluates BXCL501 (sublingual dexmedetomidine film) for acute agitation in bipolar disorder or schizophrenia at home.","Topline data expected in second half of 2025 to support sNDA for expanded IGALMI label.","Enrollment began September 2024; no safety or efficacy results reported yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176905,"accession_number":"0001104659-25-020349","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioXcel Therapeutics raises $14M in registered direct offering with warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total gross proceeds of $14M from sale of 188,383 shares and pre-funded warrants for up to 3,811,617 shares.","Combined offering price: $3.50 per share + accompanying warrant; $3.499 per pre-funded warrant + accompanying warrant.","Warrants exercisable at $4.20 per share; option warrants to purchase up to 4,000,000 additional shares.","Placement agent Rodman & Renshaw receives a 6.0% cash fee on gross proceeds.","Closing expected on first Trading Day after March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176904,"accession_number":"0001104659-25-019531","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel: FDA inspection closed with VAI; SERENITY trial enrolling; Nasdaq compliance regained; CMO resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA closed TRANQUILITY II site inspection with 'Voluntary Action Indicated'; no regulatory action taken.","SERENITY At-Home Phase 3 trial: 23 sites open, enrolling; topline data expected H2 2025 for sNDA.","Regained compliance with Nasdaq minimum bid price rule; notice received Feb 28, 2025.","Vincent J. O'Neill, M.D. resigned as EVP, Chief of Product Development and Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176903,"accession_number":"0001104659-25-009906","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioXcel Therapeutics effectuates 1-for-16 reverse stock split effective Feb 7, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-16 reverse split on Jan 29; stockholders approved at Jan 28 special meeting.","Every 16 shares of common stock reclassified into 1 share; no fractional shares, cash paid for fractions.","Split-adjusted trading begins Feb 10 under existing symbol BTAI; new CUSIP 09075P204.","Proportional adjustments to equity plans, stock options, warrants, and other convertible securities.","Reverse split does not affect authorized shares or par value; shares remain fully paid and non-assessable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176902,"accession_number":"0001104659-25-007221","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioXcel Therapeutics shareholders approve reverse stock split range of 1:5 to 1:30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 passed with ~90.8% of votes cast in favor (27.6M for, 2.5M against, 0.3M abstain).","Proposal 2 (adjournment) also approved with ~91.5% of votes cast in favor (27.7M for).","Board retains discretion to select exact split ratio between 1:5 and 1:30 at a later date.","Approximately 61.2% of outstanding common stock (30.4M shares) was represented at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176901,"accession_number":"0001104659-25-003950","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioXcel Therapeutics appoints Dr. Rajiv Patni to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from seven to eight directors on January 15, 2025.","Dr. Patni appointed as Class II director, term expiring at 2026 annual meeting.","He brings experience as CEO of Judo Bio and former CRO at Reata Pharmaceuticals.","Granted option to purchase 44,000 shares at $0.3465, vesting over three years.","Eligible for standard non-employee director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176900,"accession_number":"0001104659-25-001869","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioXcel cuts CEO/CFO/CSO 2025 cash comp, grants stock options at $0.4713","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Vimal Mehta's 2025 cash compensation reduced to $706,558; granted options for 660,000 shares at $0.4713.","CFO Richard Steinhart's cash comp reduced to $289,800; granted options for 270,000 shares.","CSO Frank Yocca's cash comp reduced to $290,500; granted options for 270,000 shares.","Options vest in 12 equal monthly installments; full acceleration on termination without cause or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193712,"accession_number":"0001104659-24-122587","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioXcel raises ~$6.2M in public offering of stock and warrants; cash runway into Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5.6M shares and warrants, plus 9M pre-funded warrants, at $0.48 per share (or $0.479 for pre-funded).","Net proceeds of ~$6.2M after underwriting discounts; use for SERENITY At-Home and TRANQUILITY In-Care trials.","Cash runway expected into Q1 2025 when combined with existing cash; potential need for additional capital.","Exercise price of 8.5M previously issued warrants reduced to $0.571 per share on Nov 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193711,"accession_number":"0001104659-24-121582","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"BioXcel Therapeutics amends Oaktree credit deal, waives covenants, sets capital raise milestones, appoints director","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment waives going concern and minimum revenue covenants; removes prior $50M raise requirement.","New capital milestones: $7M by Nov 27, $18M net by Mar 15, 2025, and $29M net by Aug 15, 2025.","Interest rate fixed at 13% (up from SOFR+7.5%) retroactive to Sep 30, 2024; 10% PIK option available.","Company must make $2.5M amortization payment by Dec 31, 2024; quarterly amortization at 5% begins Mar 31, 2026.","David Mack appointed to board; board expanded to 7. New warrants to lenders: 5M shares at $0.01/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193710,"accession_number":"0001104659-24-118261","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel Therapeutics Q3 2024 net loss narrows to $13.7M; advances Phase 3 trials for agitation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.7M in Q3 2024 vs $50.5M loss in Q3 2023; operating cash use $16.3M.","IGALMI net revenue $214k in Q3, down from $341k YoY; nine-month revenue $1.9M, up 89%.","R&D expenses $5.1M vs $19.6M; SG&A $7.7M vs $24.3M, both lower due to restructuring.","First patient randomized in SERENITY At-Home Phase 3 trial for bipolar/schizophrenia agitation; 9-12 month duration.","Cash and equivalents $40.4M as of Sept 30, 2024; patent portfolio extended to 2043."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1900000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193709,"accession_number":"0001104659-24-107327","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioXcel CCO Matthew Wiley departs; severance includes 9-mo salary, consulting through 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Wiley (SVP, Chief Commercial Officer) separated on Oct 2, 2024; severance agreement signed Oct 3.","Severance: 9 months base salary continuation, prorated 2024 bonus, 9 months COBRA reimbursement.","Consulting agreement with Wiley's LLC at $330/hr, $7,500 retainer, runs through Dec 31, 2024.","Standard release of claims and non-disparagement obligations included in separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210021,"accession_number":"0001104659-24-101689","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioXcel receives Nasdaq deficiency notices for bid price and market value; faces delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sep 16, 2024, Nasdaq notified BTAI that bid price closed below $1.00 for 30 consecutive business days.","Company has until March 17, 2025 to regain compliance; stock must close at $1.00+ for 10 consecutive days.","On Sep 20, 2024, Nasdaq notified BTAI that market value of listed securities fell below $35M minimum.","Compliance deadline for market value is March 19, 2025; must meet $35M+ for 10 consecutive days.","BTAI evaluating options; cannot assure regaining compliance; may be eligible for second 180-day period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210020,"accession_number":"0001104659-24-101176","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"BioXcel Therapeutics reduces workforce by 28% (~15 employees) to cut costs, prioritizes BXCL501; CCO Matt Wiley departs.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Headcount reduction of 28% (~15 employees) approved Sept 17, 2024; charges ~$1.4M primarily in severance and benefits, expected Q4 2024.","Company prioritizes clinical development of lead neuroscience asset BXCL501 to extend cash runway.","Chief Commercial Officer Matt Wiley's position eliminated; employment ends Oct 2, 2024, followed by consulting period.","Company previously identified substantial doubt about going concern; cost reduction aims to extend cash runway.","Majority of charges expected to be cash expenditures; plan completion by Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210019,"accession_number":"0001104659-24-098149","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel submits Phase 3 protocol for BXCL501 in Alzheimer's agitation to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted TRANQUILITY In-Care Phase 3 protocol for 60 mcg BXCL501 to FDA on Sept 5, 2024.","Trial targets agitation associated with Alzheimer's dementia.","No additional details on trial design or timeline were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210018,"accession_number":"0001104659-24-097127","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioXcel initiates patient enrollment in pivotal Phase 3 SERENITY At-Home trial for BXCL501","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial evaluates safety of 120 mcg BXCL501 (dexmedetomidine ODF) for acute agitation in bipolar or schizophrenia in the at-home setting.","Double-blind, placebo-controlled study will enroll ~200 patients; patients self-administer drug/placebo over 12-week period.","Primary objective is safety; exploratory endpoint modified CGI-C two hours after dosing; trial duration expected 9–12 months.","No changes to guidance or financial outlook; company previously disclosed substantial doubt about going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210017,"accession_number":"0001104659-24-086086","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel Q2 2024 IGALMI net revenue up 141% YoY to $1.1M; net loss narrows to $8.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IGALMI net revenue $1.1M (+141% YoY, +90% sequentially) on increased psychiatric clinic contracting.","Net loss $8.3M vs $53.5M in Q2 2023; operating cash used $23.2M; cash $56.3M at June 30.","Planning SERENITY At-Home Phase 3 for BXCL501 in agitation with bipolar/schizophrenia; TRANQUILITY In-Care Phase 3 for Alzheimer's agitation.","IGALMI PMR study showed no tachyphylaxis/tolerance/withdrawal; no serious adverse events reported.","Received USPTO Notice of Allowance for new patent expiring 2043, expected as 11th Orange Book listing for IGALMI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":1686000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210016,"accession_number":"0001104659-24-080571","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"BioXcel Therapeutics amends ARx supply agreement to reduce minimum annual payments over next three years","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment reduces specified minimum annual payment due to ARx for next three years starting 2024.","Thereafter, minimum annual payments only required if FDA approves sNDA or NDA for listed indications.","No specific financial terms or amounts disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210015,"accession_number":"0001104659-24-080022","cik":1720893,"company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioXcel reports preliminary Q2 2024 IGALMI net revenue of $1.1M, up 90% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2024 net revenue from IGALMI approximately $1.1M, up 90% from Q1 2024 and 141% from Q2 2023.","Growth driven by increased contracting with psychiatric clinics and behavioral health facilities via small commercial team.","CEO cites potential for at-home expansion if BXCL501 approved, targeting estimated 23M annual agitation episodes.","Full Q2 2024 financial results and business update to be discussed on a future earnings call (date TBD)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":1686000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41221601.09541984,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-07-16T23:59:59+00:00|210015"}